Surveillance Pathways After Vascular Interventions

9.1What surveillance is trying to catch

Surveillance begins before the patient leaves the operating room or angiography suite, because the first post-procedure study is not merely a date on a calendar. It is the reference condition against which future symptoms, pressures, waveforms, velocities, sac size, and neurologic events will be judged. The practical question is: what has been altered, what can fail, how early can that failure be recognized, and what finding would change management? Contemporary PAD guidance frames follow-up after lower-extremity treatment as a combined clinical, physiologic, medication, and selective-imaging exercise rather than a single-test ritual, while the SVS arterial follow-up guidance makes the same point from the procedural side: the arterial bed, conduit, device, and prior findings drive the surveillance plan ACC/AHA 2024 · ESVS 2024 · SVS 2018.

The first failure mode is clinical failure: recurrent pain, loss of walking distance, recurrent rest pain, wound non-healing, new tissue loss, neurologic symptoms after carotid work, dialysis dysfunction after access intervention, recurrent swelling after venous reconstruction, or new abdominal or back symptoms after aortic repair. Clinical surveillance is not a soft endpoint. It catches failures that imaging may not yet have contextualised, and it prevents technical patency from being mistaken for patient success. For PAD and CLTI, follow-up must ask whether the limb is warmer, whether wounds are closing, whether toe or ankle pressures have moved in the expected direction, whether off-loading and infection control are working, and whether secondary prevention has been implemented; the Global Vascular Guidelines place CLTI decision-making in a limb-risk, anatomy, and patient-risk framework that remains useful after revascularization because the treated limb can fail by wound biology, inflow or outflow disease, conduit disease, or systemic risk rather than by a single stenosis alone ACC/AHA 2024 · CLTI 2019.

The second failure mode is hemodynamic failure. A technically successful bypass or endovascular intervention may develop inflow disease, an anastomotic stenosis, a valve-site or conduit stenosis, in-stent restenosis, edge stenosis, or progressive outflow disease. Duplex ultrasound and physiologic testing are useful because they can convert a vague complaint or a quiet limb into a trend: a pressure drop, a waveform change, a focal velocity rise, or a loss of graft-flow reserve. The systematic review of infrainguinal bypass surveillance supports clinically familiar duplex triggers such as high peak systolic velocity and high velocity ratio as graft-threatening patterns, but the important teaching point is not to memorize one number outside context; it is to compare the finding with the conduit, baseline study, symptoms, and outflow bed Systematic Review Duplex 2017. More recent infrainguinal surveillance syntheses emphasise that protocols and velocity criteria vary, so a program should be internally consistent enough that serial studies can be interpreted rather than treated as isolated reports Duplex Ultrasound Surveillance 2026.

The third failure mode is device or seal failure. Endografts, stents, stent-grafts, and covered reconstructions can remain patent while losing seal, kinking, migrating, fracturing, narrowing at an edge, or failing to exclude the target pathology. Aortic endografts are the clearest example: the patient may feel well while the aneurysm sac enlarges or a late endoleak, seal-zone problem, or reintervention need emerges. Long-term EVAR trial follow-up, including EVAR-1 and DREAM, supports treating EVAR surveillance as a durable obligation rather than a short postoperative check Endovascular versus open 2016 · EVAR 2010. The same logic applies to carotid stenting and endarterectomy in a different clinical language: surveillance must remain tied to neurologic symptoms and restenosis risk, and CREST's long-term follow-up reinforces that carotid outcomes are judged over years rather than by the perioperative result alone SVS 2018 · CREST 2016.

The fourth failure mode is program failure. A surveillance pathway fails when the baseline study is absent, the study technique changes without documentation, the report lacks the measurement needed for comparison, the result is not routed to a clinician who can act, or the patient is lost because the pathway was built around imaging rather than a clinical owner. Vascular laboratory performance standards matter here: duplex surveillance only becomes a clinical tool when acquisition, measurement, reporting, and quality assurance are reproducible enough for serial comparison SVU Vascular Technology 2019 · SVU Professional Performance Guidelines. A good follow-up note therefore names the reconstruction, the intended failure modes, the current clinical state, the test used, the comparison study, the action criterion used locally, and the next responsibility. It should be clear whether the patient is stable, needs earlier imaging, needs cross-sectional imaging, needs medical optimization, or needs discussion for reintervention.

9.2Follow-up lanes after intervention

Surveillance lanes should be built around the reconstruction family rather than copied across the service. For an autogenous infrainguinal vein bypass, the vulnerable segment may be the inflow artery, proximal or distal anastomosis, retained valve or valve-lysis site, conduit segment, or outflow bed. The surveillance task is to protect a living conduit before thrombosis converts a correctable stenosis into graft loss. Duplex is well matched to that task because it can localise a focal lesion, compare velocities with prior studies, and place the finding beside ankle or toe pressures and wound progress. Evidence syntheses support structured infrainguinal duplex surveillance, while also showing that intensity and criteria are not uniform across studies; the safest practical rule is to establish an early post-procedure baseline, compare all later studies with that baseline, and escalate when the duplex, physiology, and clinical trajectory agree that the reconstruction is threatened ACC/AHA 2024 · Duplex Ultrasound Surveillance 2026 · Systematic Review Duplex 2017.

Prosthetic bypass surveillance asks a related but not identical question. A prosthetic graft does not remodel like vein, and the clinical catastrophe is often thrombosis or infection rather than a slowly evolving focal vein lesion. The examination should therefore include the access route to the graft, groin or wound status, pulses, limb perfusion, and any systemic signs of infection or perigraft complication. Duplex can still identify inflow, anastomotic, or outflow problems, but a stable scan in an unwell patient is not reassuring if the clinical picture suggests infection or perigraft fluid. The SVS follow-up framework is useful because it treats open bypass, endovascular therapy, carotid intervention, and aortic repair as different procedure families with different follow-up questions rather than as variations on one vascular calendar SVS 2018.

After lower-extremity endovascular therapy, the lane changes again. Balloon angioplasty, atherectomy, bare-metal stenting, drug-coated balloons, drug-eluting stents, covered stents, and hybrid procedures do not fail in the same way. Restenosis may be diffuse, focal at a stent edge, related to recoil, influenced by calcification, or driven by untreated inflow or outflow disease. A systematic review of surveillance after endovascular intervention for lower-limb PAD found wide variation in practice, which is exactly why the plan should be written as a failure-mode strategy rather than a ritual: what segment was treated, what segment remains diseased, what symptom would represent recurrence, and which test can answer the next question? PAD 2022. For many patients, the early comparison includes symptoms, pulse examination, ABI or toe pressure, and duplex; cross-sectional imaging is reserved for anatomy that duplex cannot answer, conflicting clinical and physiologic signals, suspected device complication, or planning for reintervention ACC/AHA 2024 · Duplex Ultrasound Surveillance 2026.

Aortic endograft surveillance is a separate lane because patency is not the main endpoint. The essential questions are whether the aneurysm sac is stable or shrinking, whether there is an endoleak or seal problem, whether the graft has migrated or kinked, whether branches are compromised, and whether the patient has renal, radiation, or contrast limitations that should alter modality choice. Duplex may be attractive for selected infrarenal EVAR follow-up when the sac is stable and the laboratory is reliable, but CTA or other cross-sectional imaging remains necessary when sac behavior changes, anatomy is complex, the acoustic window is poor, or the question is seal, migration, branch involvement, or reintervention planning. EVAR-1 and DREAM long-term follow-up justify maintaining this long horizon; they do not justify indefinite identical imaging in every patient regardless of sac behavior, renal function, and prior findings SVS 2018 · Endovascular versus open 2016 · EVAR 2010.

Carotid surveillance is closer to neurologic risk management than to limb salvage. After carotid endarterectomy, the questions are recurrent neurologic symptoms, restenosis at the repair, progression on the contralateral side, and durability of risk-factor treatment. After carotid stenting, the same clinical questions are filtered through a device that can develop in-stent restenosis and may generate different duplex velocity behavior than a native artery. CREST's long-term follow-up keeps perioperative outcomes and later ipsilateral stroke within the same outcome conversation, which is why a carotid follow-up pathway should not reduce itself to a single restenosis label CREST 2016. In practice, the report should state whether the patient is symptomatic, whether restenosis is suspected, whether the contralateral artery has changed, and whether the finding would alter antiplatelet, lipid, blood-pressure, or reintervention planning SVS 2018.

Dialysis access and venous intervention lanes illustrate why one arterial surveillance template cannot be exported blindly. An arteriovenous fistula or graft is monitored through access function, pressures, cannulation difficulty, delivered dialysis, aneurysmal change, infection, steal, high-output physiology, and duplex assessment of inflow, anastomosis, outflow, and central veins when clinically indicated. A venous stent or iliocaval reconstruction is followed for recurrent swelling, pain, ulcer behavior, inflow adequacy, stent patency, and outflow obstruction rather than for ABI change. These lanes need their own detailed protocols in the access and venous chapters, but the operational rule is the same as in arterial surveillance: name the reconstruction, name the failure mode, select the modality that can answer it, and avoid importing criteria from another vascular bed.

Modality selection is therefore a clinical act. Duplex is strongest when the target is accessible, serial comparison is needed, haemodynamics matter, and the laboratory can reproduce technique. CTA or MRA is stronger when the target is deep, tortuous, obscured by bowel gas or calcification, anatomically complex, or when device integrity, sac behavior, branch patency, or operative planning is the question. Catheter angiography should usually be reserved for situations in which diagnosis and treatment may occur in the same sitting or when non-invasive tests leave an actionable uncertainty. Across all lanes, the test should be chosen only after the clinician has stated what result would change management.

9.3Trials, endpoints, and prevention context

Trials shape surveillance by defining what counts as success. A limb that remains patent but fails to heal, a carotid repair that looks acceptable but is followed by neurologic events, and an EVAR that excludes the aneurysm initially but later shows sac expansion are all failures of the clinical strategy, not merely findings on different tests. The surveillance endpoint should therefore be written before the interval is chosen. For claudication, the endpoint may be walking performance and quality of life. For CLTI, it may be wound healing, absence of major adverse limb events, maintenance of perfusion, and survival. For carotid disease, neurologic freedom matters. For EVAR, sac behavior and freedom from rupture or reintervention matter. The follow-up pathway should then measure the endpoint that the intervention was meant to protect.

The CLTI strategy trials are best read in this chapter as maps of what must be protected after treatment, not as calendars. BASIL-1 showed that an initial bypass and an initial angioplasty strategy could look broadly similar in the early period, while longer-term outcomes favoured bypass-first in selected patients who survived beyond the early horizon BASIL-1 2005. BEST-CLI reinforced the importance of available vein conduit and patient selection when comparing surgical and endovascular strategies, so a patient with a good autogenous bypass requires a surveillance pathway that protects that conduit, while an endovascular-first patient requires attention to treated-segment restenosis, untreated disease, wound response, and repeat-intervention burden BEST-CLI 2022. BASIL-2, focused on infrapopliteal CLTI strategy, is a reminder that the surveillance plan must be anchored to the treated population and anatomy rather than to an all-purpose belief that one strategy always creates the same downstream risk BASIL-2 2023.

CLTI follow-up also has a wound and patient-risk layer that pure patency surveillance misses. The PLAN concept and WIfI staging framework are useful because they keep patient risk, limb severity, and anatomic complexity in the same conversation; after revascularization, that means surveillance must ask whether perfusion is adequate for the wound problem, whether infection and pressure are controlled, and whether a new hemodynamic decline explains stalled healing CLTI 2019. A duplex finding that would be observed in a healed, ambulatory, low-risk limb may carry different urgency in a patient with progressive tissue loss or threatened conduit. Conversely, a patent reconstruction does not guarantee success if infection, nutrition, renal disease, frailty, or off-loading failure prevents healing.

Prevention trials belong in surveillance because they change the consequences of a finding. VOYAGER PAD and COMPASS support the principle that PAD patients after revascularization or with symptomatic atherosclerosis remain at risk for limb and cardiovascular events that are not solved by a technically successful procedure VOYAGER 2020 · COMPASS 2018. The surveillance visit is therefore an opportunity to check antithrombotic eligibility and adherence, lipid lowering, blood-pressure control, smoking status, diabetes control, foot protection, exercise participation, and symptoms of recurrent ischemia. It should not become a medication chapter or a dosing table, but it should not ignore prevention either; otherwise the service will detect restenosis while missing the systemic risk that determines survival.

Functional endpoints are just as important in claudication. CLEVER showed that, in aortoiliac claudication, supervised exercise and primary stenting improved different patient-centred outcomes during early follow-up: exercise improved peak walking time, while stenting improved quality-of-life measures PAD 2012. That distinction matters during follow-up. A patient who walks farther but remains dissatisfied, a patient whose quality of life improves despite unchanged treadmill performance, and a patient with recurrent symptoms after a stent do not need the same response. Surveillance for claudication should ask about walking distance, functional goals, medication tolerance, exercise engagement, and recurrent hemodynamic limitation before ordering more anatomy.

Device safety signals also affect the surveillance conversation without turning it into alarmism. The 2018 Katsanos meta-analysis raised a late mortality concern for paclitaxel-coated femoropopliteal devices across 28 randomized trials and 4663 patients, with particular attention to later follow-up subsets Katsanos et al 2018. The FDA's 2023 update stated that the totality of available data no longer supported an excess mortality risk for paclitaxel-coated PAD devices FDA 2023. The practical lesson is not to create a separate imaging calendar solely because a drug-coated device was used; it is to document the device, keep long-term clinical follow-up credible, discuss risk in current terms, and avoid either dismissing prior safety concerns or freezing the service in an outdated warning.

Aortic and carotid trials similarly remind the clinician that a good early result is not the endpoint. EVAR follow-up data show why late sac behavior, rupture prevention, and reintervention remain part of the patient's lifetime relationship with the vascular service Endovascular versus open 2016 · EVAR 2010. CREST shows why carotid follow-up must combine procedural durability with neurologic outcome and systemic vascular prevention rather than reading a duplex result in isolation CREST 2016. Across territories, the right endpoint is the one that would harm the patient if missed early enough to act.

9.4Clinical checkpoint

A surveillance order should be able to survive handover. The next clinician should know the index procedure, date, anatomy treated, conduit or device used, completion result, first baseline study, current symptoms, current physiologic status, imaging comparison, medication plan, and the reason the next test is being ordered. If that information is absent, the patient may still receive scans, but the program is not truly surveilling; it is accumulating disconnected observations. The safest final check is to ask five questions: what can fail, how would the patient show it, which test detects it, what comparison is required, and what action follows?

The first handover boundary is between routine stability and event-triggered reassessment. A stable patient with a healed limb, unchanged pulses or pressures, a stable duplex, and good prevention care may remain in a predictable lane. A patient with recurrent symptoms, falling ABI or toe pressure, loss of a graft pulse, wound deterioration, neurologic symptoms, sac expansion, new endoleak concern, dialysis access dysfunction, or recurrent venous congestion leaves the routine lane and needs a focused question. PAD guidelines support combining clinical review, physiologic testing, and selective imaging after lower-extremity revascularization; SVS arterial follow-up guidance supports adjusting the plan to the arterial bed and procedure rather than forcing one schedule onto every reconstruction ACC/AHA 2024 · SVS 2018. The result should be an action statement, not merely a test result.

The second boundary is between duplex and cross-sectional imaging. Duplex is often the best serial tool for accessible infrainguinal bypasses, many lower-extremity endovascular segments, carotid repairs, and selected aortic follow-up when the question is hemodynamic and the laboratory is reliable. Its weakness is not that it is inferior technology; it is that it can be the wrong technology for deep anatomy, poor windows, complex endograft questions, branch assessment, or reintervention planning. Cross-sectional imaging is not automatically better, because contrast, radiation, renal function, metal artefact, and incidental findings create their own harms. Vascular laboratory standards and surveillance syntheses both point toward the same operational answer: choose a reproducible modality for the question at hand and maintain comparability over time Duplex Ultrasound Surveillance 2026 · PAD 2022 · SVU Vascular Technology 2019.

The third boundary is between detection and intervention. Not every abnormal velocity, mild restenosis, small endoleak concern, or recurrent symptom mandates immediate repair. The decision to intervene depends on the territory, the threatened endpoint, the trajectory of change, the patient’s risk, and the probability that treatment will improve outcome rather than simply reset the surveillance clock. For infrainguinal bypass, a graft-threatening duplex pattern with compatible physiologic or clinical change is different from a modest isolated abnormality in a stable limb; the bypass surveillance literature supports using velocity patterns as danger signals, but they should be interpreted with the baseline study and clinical state Systematic Review Duplex 2017. For EVAR, sac enlargement or suspected clinically important endoleak changes the question from surveillance to problem-solving; late EVAR follow-up data justify taking that transition seriously Endovascular versus open 2016.

The fourth boundary is between anatomy and patient outcome. A technically patent reconstruction does not complete CLTI care if wounds fail to heal, infection persists, off-loading fails, or systemic illness overwhelms limb recovery. The CLTI trial family and global guideline framework both argue against surveillance that watches only the treated segment: the endpoint is limb status and patient survival, not a pristine image CLTI 2019 · BASIL-2 2023 · BEST-CLI 2022 · BASIL-1 2005. Similarly, a claudication program that monitors stent patency but never asks about walking goals has missed the patient's reason for treatment; the CLEVER findings make function and quality of life legitimate follow-up endpoints, not optional extras PAD 2012.

The fifth boundary is between surveillance and prevention. A PAD patient who returns for duplex after revascularization should also have antithrombotic strategy, lipid therapy, blood-pressure control, smoking, diabetes, renal function, foot protection, and exercise reviewed because limb events and cardiovascular events share the same patient. VOYAGER PAD and COMPASS support integrating limb and cardiovascular prevention into the follow-up encounter, while the paclitaxel safety sequence shows why device-specific risk discussions should be kept current and proportionate Katsanos et al 2018 · VOYAGER 2020 · COMPASS 2018 · FDA 2023. Surveillance is strongest when the imaging result triggers a whole-patient check, not when it replaces one.

The final product of a good surveillance pathway is a short, explicit plan: current status, risk lane, next test, trigger for earlier reassessment, and owner of the result. For a vein bypass, that may mean continued duplex and physiologic comparison with urgent reassessment for a new focal velocity pattern, pressure drop, wound deterioration, or symptom recurrence. For an endovascular limb intervention, it may mean symptom and physiology-led review with duplex of the treated segment and cross-sectional imaging only when anatomy or reintervention planning requires it. For EVAR, it may mean sac-based follow-up with modality chosen by prior sac behavior, renal risk, and the need to answer an endoleak or seal question. For carotid repair, it may mean neurologic review, contralateral disease awareness, and duplex comparison interpreted in light of whether the repair was endarterectomy or stenting. For access and venous interventions, it means keeping their own physiologic endpoints separate from arterial limb-surveillance habits. The common discipline is simple: do not surveil because a date arrived; surveil because a defined failure would harm the patient and the chosen test can detect it early enough to act.